Pfizer says new studies show higher dose of Lipitor slows atherosclerosis
26 Mar 2007
LONDON (AFX) - Pfizer Inc said results from two new imaging trials show a higher dose of its cholesterol-fighting drug Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH).
The results are part of three, two-year clinical trials, involving over 2,800 patients, designed to investigate the efficacy of torcetrapib in combination with Lipitor compared to Lipitor alone.
Read the full report from here @ Forbes
No comments:
Post a Comment